PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 316281

Rapid assay for von Willebrand factor activity using formalin-fixed platelets and microtitration technic.

R Ramsey·B L Evatt
View original source ↗Export metadata ↓

Abstract

An inexpensive assay for von Willebrand factor using microtitration plates, formalin-fixed platelets, and ristocetin is described. With this technic, the assay for von Willebrand factor is simple enough to be considered for use in any diagnostic laboratory for patients with prolonged bleeding times.

Explore related subjects

Blood Coagulation FactorsBlood Coagulation TestsBlood PlateletsFactor VIIIFemaleFormaldehydeHumansMaleMethodsRistocetinvon Willebrand Diseasesvon Willebrand FactorComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Ramsey, B L Evatt. 1979. Rapid assay for von Willebrand factor activity using formalin-fixed platelets and microtitration technic.. https://doi.org/10.1093/ajcp%2F72.6.996

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII.

We report our experience with a small child with severe factor VII deficiency and a history of frequent and spontaneous life-threatening hemorrhage. The patient has received several years of successful prophylactic treatment with an every 3-day infusion program in which she receives recombinant activated factor VII (rVIIa) using multiple doses from a single reconstituted vial over a 72-hr period. Comparison is made to prophylactic treatment in this same patient using plasma-derived factor VII (PDVII) using a prothrombin complex concentrate (PCC).

Blood Coagulation Factors↗
PubMed2007

Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.

Prothrombin complex concentrates (PCC) have been used as bypassing agents for the treatment of haemophilia A patients with inhibitor as well as for replacement therapy in congenital and acquired deficiencies of vitamin-K-dependent clotting factors. The efficacy of PCC is variable, however, especially during long-term and high-dose use, and all currently available products of this nature contain heparin. We have examined the haemostatic properties of PCC using reconstituted whole blood made by mixing coagulation-factor-deficient plasma and washed blood cells. In rotation thromboelastometry (ROTEM), the recommended therapeutic dose of Proplex ST corrected the abnormal patterns. At higher concentrations, however, the ROTEM patterns regressed. In addition, specific assays of coagulation factors appeared unreliable in the presence of 2.5 U/ml Proplex ST; the abnormalities were corrected when protamine sulfate was added. The findings suggest that the presence of heparin in PCC might have a greater effect on global haemostasis. Careful attention to the anticoagulant effect as well as thrombogenicity of PCC is required. Monitoring therapy using such as ROTEM analysis could be highly informative.

Blood Coagulation Factors↗